Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation

Overview of attention for article published in Tumor Biology, December 2014

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

blogs: 1 blog

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 26 Mendeley

Summary Blogs Dimensions citations

So far, Altmetric has seen 1 blog post.

AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation

Pharmaceutical Intelligence, 31 Jan 2016

AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation Stephen J. Williams, Ph.D.…